Strategic partnerships advance our efforts to pioneer new research, deliver new treatments and advance patient care.
Partnering with Acadia
We can’t create life-changing medicines alone. We actively seek partnerships and collaborations that drive the science of treating central nervous system disorders forward.
Successfully developing the first FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis is a testament to our commitment to partnerships through all stages of clinical and commercial life cycle.
Finding the Right Partnerships
When considering partners, we focus on a range of criteria to ensure each collaboration is the right fit.
- Evaluation: Our evaluation process includes a focus on differentiated science and novel product candidates in areas with significant unmet need.
- Focus Areas: Our ideal partnerships are within our strategic focus areas of CNS disorders (neurology and psychiatry) and genetic diseases.
- Phase: We are interested in opportunities from pre-clinical through Phase 3 programs to commercial-stage products.
Our Current Partnerships
Our partnerships are an important part of our mission to trailblaze innovative neuroscience solutions.
Acadia holds an exclusive Global License Agreement with Neuren Pharmaceuticals for the development and commercialization of trofinetide for Rett syndrome and other indications. Additionally, Acadia holds exclusive worldwide rights to NNZ-2591 in both Rett syndrome and Fragile X syndrome. NNZ-2591 is currently under development by Neuren in four other rare neurodevelopmental syndromes.
Acadia and Stoke Therapeutics have a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1, MECP2 (Rett syndrome) and an undisclosed CNS target of mutual interest.
Warren Center for Neuroscience Drug Discovery
Acadia and Vanderbilt University have an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of CNS disorders. The collaboration is focused on positive allosteric modulators (PAM) of the M1 receptor.
Highly selective PAM of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders.
Partner with Us
We welcome the opportunity to learn how we can work together. To further explore partnering opportunities, please contact us.